Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Compound synergistic tylosin tartrate

A tylosin tartrate and compound technology, which is applied in the direction of antibacterial drugs, pharmaceutical formulas, medical preparations containing active ingredients, etc., can solve the problems of incomplete curative effects, etc., and achieve long-lasting drug effects and rapid onset of effects , less stimulating effect

Active Publication Date: 2013-11-27
金河牧星(重庆)生物科技有限公司
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The dosage of the injection is accurate and the effect is reliable, unlike the oral medicine that may be affected by digestive juices, food, etc., so that the dose taken cannot fully produce the curative effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound synergistic tylosin tartrate
  • Compound synergistic tylosin tartrate
  • Compound synergistic tylosin tartrate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Tylosin tartrate 1g, kanamycin sulfate 1g, trimethoprim 0.2g, citric acid 0.2g, procaine hydrochloride 0.05g.

[0033] Preparation:

[0034] Respectively take trimethoprim and citric acid of the prescribed amount, mix them and pulverize them through a flow energy mill, pass through a 120 mesh sieve, and then deliver them in equal amounts with tylosin tartrate, kanamycin sulfate, and procaine hydrochloride. Addition, mixing evenly, inspection of semi-finished products, packaging, packaging, inspection of finished products, that is to say.

Embodiment 2

[0036] Tylosin tartrate 1g, kanamycin sulfate 1g, trimethoprim 0.2g, succinic acid 0.2g, procaine hydrochloride 0.05g.

[0037] Preparation:

[0038] Weigh respectively the prescribed amount of trimethoprim and succinic acid, mix them and pulverize them through a flow energy mill, pass through a 120-mesh sieve, and then add them with tylosin tartrate, kanamycin sulfate, and pain relieving agents in equal amounts. Mix evenly, inspect the semi-finished product, subpackage, pack, inspect the finished product, and put it into storage.

Embodiment 3

[0040] Tylosin tartrate 1g, kanamycin sulfate 1g, trimethoprim 0.2g, citric acid 0.2g, lidocaine hydrochloride 0.05g.

[0041] Preparation:

[0042] Respectively weigh trimethoprim and citric acid in the prescribed amount, mix them, pass through a flow energy mill, pass through a 150-mesh sieve, and then mix them with tylosin tartrate, kanamycin sulfate, and pain relieving agents in equal increments Uniformity, inspection of semi-finished products, sub-packaging, packaging, inspection of finished products, warehousing, and ready to go.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a compound synergistic tylosin tartrate. The invention aims to provide an compound synergistic tylosin tartrate for injection for livestock, which has quick and definite curative effect on livestock and fowl respiratory system infections and complications. The medicine is composed of the following components in parts by weight: 1 part of tylosin tartrate, 1 part of kanamycin sulfate, 0.2 part of trimethoprim, 0.2 part of cosolvent and 0.05-0.1 part of pain relieving agent. The cosolvent is citric acid or succinic acid or compound of both, and the pain relieving agent is procaine hydrochloride or lidocaine hydrochloride or compound of both. The compound synergistic tylosin tartrate for injection for livestock contains the three pharmaceutical components, including tylosin tartrate, kanamycin sulfate and trimethoprim. The invention solves the problem of incapability of well controlling the secondary infection due to the narrow antimicrobial spectrum of the tylosin tartrate in treating mycoplasma infection, solves the problem of insolubility of trimethoprim in water, has a synergistic effect on tylosin tartrate and kanamycin sulfate, and is accurate in dosage and convenient to use.

Description

[0001] This application is a divisional application of the invention patent with the application number: 201210277167.3 and the patent name: "Compound Synergistic Tylosin Tartrate for Veterinary Injection". The original application date: August 06, 2012. technical field [0002] The invention relates to compound synergistic tylosin tartrate for veterinary injection. Background technique [0003] Judging from the current development of my country's animal husbandry industry, the current high incidence of respiratory infections in livestock and poultry, serious complications, and great harm to livestock and poultry. Also do not have comparatively desirable therapeutic drug treating both symptoms and root causes on the market now. Through investigation and research on the domestic and international markets, it is found that the market is in urgent need of a drug that has a stable drug effect, good curative effect, high stability, and is easy to use, and has special effects on l...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61K9/14A61P31/04A61P29/00A61P11/00A61K31/7036A61K31/505A61K31/167A61K31/245
Inventor 陈益德胡学全周可刚何丽花刘亚
Owner 金河牧星(重庆)生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com